儿童斑秃新型靶向药物治疗研究进展

doi:10.35541/cjd.20230660

Abstract

Abstract: 【Abstract】 In recent years, a variety of small-molecule targeted drugs and biological agents have shown promising efficacy and good safety for alopecia areata in clinical studies. Several targeted drugs have been approved for the treatment of moderate to severe pediatric alopecia areata in China and other countries. This review summarizes the recent progress in the application of these drugs for pediatric alopecia areata.

Key words: Alopecia areata, Biological agents, Child, JAK-STAT inhibitors, Treatment

Wei Ran, Li Qinfeng. Novel targeted drugs for the treatment of pediatric alopecia areata[J]. Chinese Journal of Dermatology,2024,e20230660. doi:10.35541/cjd.20230660

References ［30］

［1］	Bhardwaj P, Basu D, Podder I, et al. Clinico⁃epidemiological profile of childhood alopecia areata along with dermoscopic correlation: a cross⁃section, observational study［J/OL］. Indian Dermatol Online J, 2021,12（2）:250⁃257. doi: 10.4103/idoj.IDOJ_451_20.
［2］	Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2020,82（3）:675⁃682. doi: 10.1016/j.jaad.2019.08.032.
［3］	Peloquin L, Castelo⁃Soccio L. Alopecia areata: an update on treatment options for children［J］. Paediatr Drugs, 2017,19（5）:411⁃422. doi: 10.1007/s40272⁃017⁃0239⁃z.
［4］	Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（4）:1164⁃1166. doi: 10.1016/j.jaad.2018.12.041.
［5］	Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children［J］. J Am Acad Dermatol, 2019,80（2）:568⁃570. doi: 10.1016/j.jaad.2018.08.041.
［6］	Jerjen R, Meah N, Trindade de Carvalho L, et al. Treatment of alopecia areata in pre⁃adolescent children with oral tofacitinib: a retrospective study［J］. Pediatr Dermatol, 2021,38（1）:103⁃108. doi: 10.1111/pde.14422.
［7］	Huang J, Li T, Tan Z, et al. Effectiveness of tofacitinib in pre⁃adolescent alopecia areata: a retrospective case series and literature review［J］. Acta Derm Venereol, 2023,103:adv13418. doi: 10.2340/actadv.v103.13418.
［8］	刘元香, 梁源, 赵欣荣, 等. JAK抑制剂治疗儿童重症斑秃5例［J］. 中华皮肤科杂志, 2023,56（9）:849⁃852. doi: 10.35541/cjd. 20220317.
［9］	Dube V. Recovery of alopecia universalis with associated nail dystrophy treated with tofacitinib: a 6⁃year⁃old child's case report［J］. Int J Trichology, 2021,13（6）:32⁃33. doi: 10.4103/ijt.ijt_91_21.
［10］	Iorizzo M, Haneke E. Tofacitinib as treatment for nail lichen planus associated with alopecia universalis［J］. JAMA Dermatol, 2021,157（3）:352⁃353. doi: 10.1001/jamadermatol.2020.4555.
［11］	Asfour L, Bokhari L, Bhoyrul B, et al. Treatment of moderate⁃to⁃severe alopecia areata in pre⁃adolescent children with baricitinib［J］. Br J Dermatol, 2023,189（2）:248⁃250. doi: 10.1093/bjd/ljad118.
［12］	Rotaru S, Common M, Mahé E. Severe inflammatory tinea capitis in a child receiving baricitinib therapy for alopecia areata［J］. Ann Dermatol Venereol, 2023,150（2）:160⁃161. doi: 10.1016/j.annder.2023.02.001.
［13］	Fiocco Z, Kerl K, French LE, et al. Disseminated tinea corporis under baricitinib therapy for atopic dermatitis［J］. Dermatol Ther, 2022,35（4）:e15351. doi: 10.1111/dth.15351.
［14］	Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（2）:566⁃568. doi: 10.1016/j.jaad.2018.08.040.
［15］	Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2019,33（5）:850⁃856. doi: 10.1111/jdv.15489.
［16］	Ali NS, Tollefson MM, Lohse CM, et al. Incidence and comorbidities of pediatric alopecia areata: a retrospective matched cohort study using the Rochester Epidemiology Project［J］. J Am Acad Dermatol, 2022,87（2）:427⁃429. doi: 10.1016/j.jaad.2021.08.050.
［17］	Bourkas AN, Sibbald C. Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report［J］. SAGE Open Med Case Rep, 2022,10:2050313X221138452. doi: 10.1177/2050313X221138452.
［18］	Yu D, Ren Y. Upadacitinib for successful treatment of alopecia universalis in a child: a case report and literature review［J］. Acta Derm Venereol, 2023,103:adv5578. doi: 10.2340/actadv.v103.5578.
［19］	King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double⁃blind, multicentre, phase 2b⁃3 trial［J］. Lancet, 2023,401（10387）:1518⁃1529. doi: 10.1016/S0140⁃6736（23）00222⁃2.
［20］	Zhao J, Liu L. A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib［J］. JAAD Case Rep, 2022,22:99⁃100. doi: 10.1016/j.jdcr.2022.02.027.
［21］	Huang J, Liu O. Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib［J］. J Cosmet Dermatol, 2024,23（1）:348⁃349. doi: 10.1111/jocd.15896.
［22］	Keren A, Shemer A, Ullmann Y, et al. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo［J］. J Dermatol Sci, 2015,77（1）:74⁃76. doi: 10.1016/j.jdermsci.2014.11.009.
［23］	Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo⁃controlled single⁃center pilot study of the safety and efficacy of apremilast in subjects with moderate⁃to⁃severe alopecia areata［J］. Arch Dermatol Res, 2019,311（1）:29⁃36. doi: 10.1007/s00403⁃018⁃1876⁃y.
［24］	Chhabra G, Verma P. Steroid⁃resistant alopecia totalis in a child successfully treated with oral apremilast and platelet⁃rich plasma therapy［J］. Dermatol Ther, 2019,32（6）:e13082. doi: 10.1111/dth.13082.
［25］	Patruno C, Napolitano M, Ferrillo M, et al. Dupilumab and alopecia: a janus effect［J］. Dermatol Ther, 2019,32（5）:e13023. doi: 10.1111/dth.13023.
［26］	Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata［J］. J Am Acad Dermatol, 2023,88（3）:651⁃653. doi: 10.1016/j.jaad.2019.06.010.
［27］	Cho SK, Craiglow BG. Dupilumab for the treatment of alopecia areata in children with atopic dermatitis［J］. JAAD Case Rep, 2021,16:82⁃85. doi: 10.1016/j.jdcr.2021.07.015.
［28］	McKenzie PL, Castelo⁃Soccio L. Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis［J］. J Am Acad Dermatol, 2021,84（6）:1691⁃1694. doi: 10.1016/j.jaad.2021.01.046.
［29］	Aleisa A, Lim Y, Gordon S, et al. Response to ustekinumab in three pediatric patients with alopecia areata［J］. Pediatr Dermatol, 2019,36（1）:e44⁃e45. doi: 10.1111/pde.13699.
［30］	Ortolan LS, Kim SR, Crotts S, et al. IL⁃12/IL⁃23 neutralization is ineffective for alopecia areata in mice and humans［J］. J Allergy Clin Immunol, 2019,144（6）:1731⁃1734.e1. doi: 10.1016/j.jaci. 2019.08.014.

[1]	Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis [J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88.
[2]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.
[3]	Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.
[4]	Yang Zijing, Chen Lihong, Ruan Yeping, Wen Wanting, Zhang Jiayi, Wang Hailun, Pan Meng, Zhao Xiaoqing. Efficacy and safety of dupilumab in the treatment of atopic dermatitis in the elderly [J]. Chinese Journal of Dermatology, 2025, 58(1): 65-69.
[5]	Jiang Junqing, Qi Xiaoli, Li Qunyan, Gu Ankang, Zhang Litao. Benign lymphoplasmacytic plaque in a child [J]. Chinese Journal of Dermatology, 2024, 57(9): 821-824.
[6]	Jing Danrui, Chen Hao, Feng Suying, Li Xiaofang, Wang Xiaopo. A case of cutaneous chronic active Epstein-Barr virus disease manifesting as persistent erythema multiforme [J]. Chinese Journal of Dermatology, 2024, 57(9): 815-820.
[7]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[8]	Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742.
[9]	Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 57(8): 743-746.
[10]	Xia Manqi, Shao Lei, Huang Qiongxiao, Tian Xin, Liang Yimin, Huang Ting, Liang Jingyao, Liu Yumei. Efficacy and safety of dupilumab in the treatment of prurigo nodularis: a multicenter retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(8): 679-684.
[11]	Luo Li, Zhang Bona, Wu Wei, Tang Wenjing, Li Yuehua, Liu Xiaoli, Ma Yanan, Li Cuicui, Qi Mengyan, Sun Ni, Shi Qiong. Efficacy and safety of 308-nm excimer laser and 308-nm excimer lamp in the treatment of 194 children with vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(8): 721-727.
[12]	Yang Kaiying, Tian Bowen, Lan Chaoting. Untargeted metabolomics analysis-based metabolic characterization of hemangioma-derived endothelial cells [J]. Chinese Journal of Dermatology, 2024, 57(7): 601-609.
[13]	Diao Ping, Han Chenglong, Liu Lian, Zhou Hui, Li Erlong, Jiang Xian. Efficacy and influencing factors of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of adult patients with port-wine stains: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(7): 595-600.
[14]	Zhang Ting, Liu Lian, Chen Haotian, Wei Danfeng, Liu Xu, Diao Ping, Liu Qingfeng, Jiang Xian. Efficacy of 595-nm pulsed dye laser in the treatment of port‐wine stains in 155 infants and toddlers: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(7): 610-615.
[15]	Zhang Sheng, Wang Xiuwei, Chen Jianyou, Deng Wei, Zhang Haihua, Zhang Gaolei, Liu Xiaoyan, Su Wei. Efficacy of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of facial port-wine stains in 15 children with Sturge-Weber syndrome [J]. Chinese Journal of Dermatology, 2024, 57(7): 616-622.

Novel targeted drugs for the treatment of pediatric alopecia areata

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［30］

Related Articles 15

Metrics

Comments

Recommended 10